CTIS2023-507774-41-00招募中1 期
MQ01
MabQuest S.A.0 个研究点目标入组 30 人开始时间: 2023年10月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart FailureCTIS2022-500347-20-00Anacardio AB116
进行中（未招募）
1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864Advanced MelanomaCTIS2023-507377-17-00Microbiotica Limited40
进行中（未招募）
1 期
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy ParticipantsInflammatory diseaseMedDRA version: 20.0Level: LLTClassification code: 10021426Term: Immune system disorder (NOS) Class: 10021428CTIS2023-503917-31-00Immunorx Pharma Inc.81
进行中（未招募）
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergyCTIS2023-505783-11-00Alk-Abello A/S12
招募中
1 期
MK-4646 Single Ascending Dose Study and DDI in Healthy ParticipantsHIV infectionMedDRA version: 20.1Level: PTClassification code: 10000807Term: Acute HIV infection Class: 100000004862CTIS2024-510899-20-00Merck Sharp & Dohme LLC28